Loading...
Loading...
BELITE BIO, INC
BELITE BIO, INC. Spoken Alpha tracks BLTE's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks BLTE's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BLTE.
curl https://api.spokenalpha.com/v1/companies/BLTE| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.23 | $1.91 | +16.9% | +2.3% | +4.8% |
| Q4 FY2026 | $2.12 | $1.89 | +12.4% | -0.7% | -0.4% |
| Q3 FY2026 | $2.23 | $1.89 | +18.0% | -3.7% | -2.0% |
| Q2 FY2026 | $2.09 | $1.77 | +18.3% | +4.6% | +4.9% |
| Q1 FY2025 | $2.06 | $1.79 | +15.2% | -2.6% | -0.3% |
| Q4 FY2025 | $2.20 | $2.03 | +8.4% | +1.6% | +4.0% |
| Q3 FY2025 | $2.02 | $1.82 | +10.9% | +1.1% | +3.6% |
| Q2 FY2025 | $2.30 | $2.04 | +12.8% | -0.3% | -1.7% |
| Q1 FY2024 | $2.46 | $2.09 | +17.7% | -0.1% | -1.8% |
| Q4 FY2024 | $2.09 | $1.93 | +8.3% | +2.6% | -0.1% |